Annovis Bio, Inc. (ANVS)
NYSE: ANVS · Pharmaceutical Preparations · Malvern, PA · filing with the SEC since 2010
Who owns Annovis Bio, Inc.
As filed with the SECHolders of 5% or more
1
Highbridge Capital Management, LLC holds 6.1% of Common Stock, par value $0.0001 per share, as its SCHEDULE 13G filed Aug 14, 2026 says.
Directors and officers
3
report now, of 9 people on the record since 2020. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 1 named at left.
Holders of 5% or moreshare of the class, as filed
Highbridge Capital Management, LLC
SCHEDULE 13G · filed Aug 14, 2026 · Common Stock, par value $0.0001 per share
Empery Asset Management, LP
SCHEDULE 13G/A · filed Oct 15, 2026 · Common Stock, $0.0001 par value per share · reported falling below 5%, from 5.64% in Jul 29, 2026
CVI Investments, Inc.
SCHEDULE 13G/A · filed May 12, 2025 · Common Stock, par value $0.0001 per share · reported falling below 5%, from 5.1% in Feb 10, 2025
What ANVS reports owning in othersstakes of 5% or more, and other ties
Annovis Bio, Inc. reports no stake in another company in the record.
Insider tradesForm 4
0sales
18purchases
0sales on a scheduled plan
0people selling
$0sold, in dollars
$7.3Mbought, in dollars
Open-market trades on Form 4 from Nov 6, 2025 to Nov 6, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Nov 6, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window1 of 9 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Hoffman Michael B | director | 0 | $0 | 0 | 18 | $7.3M |